MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, CRSP made $3,510,000 in revenue. -$578,618,000 in net income. Net profit margin of -16484.84%.

Income Overview

Revenue
$3,510,000
Net Income
-$578,618,000
Net Profit Margin
-16484.84%
EPS
-$6.47
Unit: Dollar
Revenue Breakdown
    • Grant

Unit: Dollar
Income Statement
2025-12-31
Total revenue
3,510,000
Research and development
284,806,000
Acquired in-process research and development
96,253,000
General and administrative
73,542,000
Collaboration expense, net
213,480,000
Total operating expenses
668,081,000
Loss from operations
-664,571,000
Other income, net
86,606,000
Total other income, net
86,606,000
Net loss before income taxes
-577,965,000
Provision for income taxes
3,634,000
Net loss
-581,599,000
Foreign currency translation adjustment
95,000
Unrealized gain (loss) on marketable securities
2,886,000
Comprehensive loss
-578,618,000
Basic net (loss) income per common share
-6.47
Basic weighted-average common shares outstanding
89,925,109
Diluted net (loss) income per common share
-6.47
Diluted weighted-average common shares outstanding
89,925,109
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$578,618,000 Unrealized gain (loss) onmarketable securities$2,886,000 Foreign currencytranslation adjustment$95,000 Net loss-$581,599,000 Other income, net$86,606,000 Provision for income taxes$3,634,000 Net loss beforeincome taxes-$577,965,000 Total other income,net$86,606,000 Grant$3,510,000 Loss from operations-$664,571,000 Total revenue$3,510,000 Total operatingexpenses$668,081,000 Collaboration expense, net$213,480,000 General andadministrative$73,542,000 Acquired in-processresearch and development$96,253,000 Research and development$284,806,000

CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG (CRSP)